DEA Investigation Defense: Responding to Drug Enforcement Agents

DEA Investigation Defense: Responding to Drug Enforcement Agents

The investigation is over before you know it has begun. The agents who appear at your door are not beginning their work; they are confirming what months of database analysis, prescription monitoring, and financial review have already suggested. You do not know what they know, and that asymmetry is the point.

Most people who contact a defense attorney after a DEA encounter describe the same thing: a silence they did not recognize as dangerous until it was too late. That silence is the first thing we address.

The Timeline You Did Not See

In most of the federal drug cases this firm has handled, the client’s first contact with a DEA agent occurred somewhere between month twenty-four and month thirty of an investigation the client did not know existed. The Automation of Reports and Consolidated Orders System, known as ARCOS, tracks every Schedule II and III controlled substance from manufacturer to dispenser, and the DEA can query it without judicial authorization.

Prescription Drug Monitoring Programs operate at the state level but feed into federal analysis. Financial institutions file Suspicious Activity Reports. Informants provide tips that are never attributed. By the time agents present themselves, they have already put together a narrative from your prescribing data, your dispensing records, and your financial transactions. The databases do not require a warrant, and the agents do not require your cooperation to access them.

Informed Consent Under 21 CFR 1316

DEA Form 82, the Notice of Inspection of Controlled Premises, is the document that separates a defensible case from a conceded one. The form permits an administrative inspection of a DEA registrant’s premises: a pharmacy, a clinic, a physician’s office. The form itself states, in its own text, that you possess the constitutional right to refuse.

But the form does not read itself aloud. The first letter arrives without warning, or the agents appear on a Tuesday afternoon when the waiting room is full, and the instinct is to cooperate because refusal feels like guilt. Refusing to consent is not obstruction; it is the exercise of a right printed on the document the agent has handed you. Under 21 CFR 1316.08, the written consent must reflect your understanding that anything of an incriminating nature discovered during the inspection may be seized and used against you in a criminal prosecution. That language is on the form. It is not emphasized.

What happens next is predictable: the agents leave, apply for an administrative inspection warrant from a federal district court (a warrant that does not require probable cause, only a description of the proposed inspection), and return. The inspection proceeds under the scope defined by the warrant rather than the scope defined by whatever the agents choose to examine.

We advise withholding consent in most circumstances, not because it prevents the inspection, but because it introduces a boundary the government must respect and a record we can later examine. The standard advice in this area of practice is to cooperate early and demonstrate good faith. We have observed what that cooperation produces in the hands of agents who arrived with a theory they intended to confirm. The boundary imposed by a warrant gives us something to review, something to challenge, and something that constrains the government’s access to patient records, financial data, and employee interviews that would otherwise proceed without limit.

Something like half the registrants we consult tell us they answered questions during the inspection that went well beyond what the form authorized. The agents asked about billing practices, patient relationships, personal finances. None of that falls within the scope of an administrative inspection under the Controlled Substances Act, but in a room with two federal agents and no attorney, the scope of the conversation is whatever the agents decide it is.

Most registrants who contact us do so after signing.

Parallel Construction and the Concealment of Evidence

In 2013, a Reuters investigation revealed that the DEA’s Special Operations Division had been instructing agents on how to reconstruct the origins of their cases. The term for this practice is parallel construction.

An agent receives intelligence, perhaps from an NSA intercept or a tip funneled through the Hemisphere phone records program, that a particular vehicle will be carrying narcotics along a particular route. Rather than disclose the source (which would expose the surveillance method to legal challenge), the agent arranges for a traffic stop based on a minor violation, and the search that follows appears to be the product of routine law enforcement. The chain of evidence presented to the court omits the first link. The defendant and the defendant’s attorney never see it.

The Ninth Circuit, in United States v. Alverez-Tejeda, examined one such ruse and found it constitutionally permissible (a conclusion that treats the presence of independent probable cause as a cure for institutional dishonesty), reasoning that probable cause existed independently of the deception. That reasoning is cold comfort to the defendant who cannot examine the true origin of the evidence against him.

I am less certain about the reach of this argument in circuits outside the Second and Ninth, where the case law on disclosure obligations remains thin. What we do in practice is request, early and in writing, all materials related to the origin of the investigation, including any referrals from intelligence agencies, any queries of the Hemisphere database, and any communications with the Special Operations Division. The government typically resists. The request itself, however, creates a record, and records have a way of becoming relevant at stages of litigation that no one anticipated.

Whether a federal court will ever require the government to disclose the true origin of an investigation in a routine drug case is a question no one has answered with finality.

Administrative Consequences and Registration

Before any criminal charge is filed, the DEA possesses the authority to suspend or revoke a practitioner’s registration. A show cause order initiates the process, and the hearing that follows resembles a trial: witnesses, exhibits, cross-examination, an administrative law judge.

The losing party in a registration proceeding has often already lost the ability to practice, because the investigation itself, once disclosed, tends to trigger parallel inquiries from state licensing boards, hospital credentialing committees, and insurance networks. A physician whose DEA registration is under review may find, within weeks, that the state medical board has opened its own case, that hospital privileges have been suspended pending the outcome, and that insurance panels have quietly removed the physician’s name from their provider lists. The registration proceeding is the visible event. The collateral damage is the one that ends careers.

The standard approach among firms that handle these matters is to treat the administrative proceeding as separate from any potential criminal exposure, addressing each on its own track. Treating administrative and criminal exposure as separate matters assumes the government will respect the boundary between them, which is not always the case. We treat every administrative matter as though it will become a criminal one, because in our experience, the transition is quiet and it is fast.

What to Say When Agents Appear

The sentence that matters most is the shortest one you will speak. When agents arrive, whether at a practice, a pharmacy, or a residence, the response that preserves the most options is this: “I decline to consent to this inspection without first consulting with my attorney.”

You do not need to explain why. You do not need to schedule a follow-up meeting or promise future cooperation. The agents may express frustration, or suggest that refusal will make things worse, or imply that innocent people do not need attorneys.

These are techniques, not truths.

The records on the desk, the prescriptions in the system, the text messages on the phone: none of that changes because you declined to discuss it without counsel. What changes is who controls the sequence in which that information is examined, and under what constraints.

And there is a broader principle at work here, one that extends past the specific mechanics of DEA enforcement. The federal government investigates with patience. It accumulates evidence over years, in silence, through systems designed to operate without your knowledge or participation. The moment an agent speaks to you is not the beginning of that process. It is the point at which the government has decided it possesses enough to act and would prefer a confession to confirm what the data already shows.

The response to that moment is not cooperation. It is not hostility. It is the recognition that you are entering a proceeding in which the other side has been preparing for years and you have been preparing for seconds. The only rational act is to close that gap before you say another word.

• Contact an attorney before signing any document presented by a DEA agent
• Do not alter, delete, or relocate any records after learning of the investigation
• Request a copy of any warrant or administrative subpoena presented
• Document the names, badge numbers, and statements of every agent involved

A consultation is where this begins: a conversation in which we determine what the government already possesses, what it is still assembling, and what, if anything, can be done about the distance between the two.